RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00059887.xml
CC BY 4.0 · Brazilian Journal of Oncology 2025; 21
DOI: 10.1055/s-0045-1807969
DOI: 10.1055/s-0045-1807969
PUBLIC POLICY, ACCESS, PHARMACOECONOMICS AND HEALTH MANAGEMENT
1950
POSTER PRESENTATION
Cost-effectiveness analysis of CDK4/6 inhibitors as first and second line treatments in patients with HR+ HER2- metastatic breast cancer
Authors
Keywords
cost-effectiveness analysis - Metastatic breast cancer - CDK4/6 inhibitors - healthcare economics - price negotiationsPublikationsverlauf
Artikel online veröffentlicht:
06. Mai 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Bibliographical Record
Juliana Lenzi, Andre Deeke Sasse. Cost-effectiveness analysis of CDK4/6 inhibitors as first and second line treatments in patients with HR+ HER2- metastatic breast cancer. Brazilian Journal of Oncology 2025; 21.
DOI: 10.1055/s-0045-1807969
Juliana Lenzi, Andre Deeke Sasse. Cost-effectiveness analysis of CDK4/6 inhibitors as first and second line treatments in patients with HR+ HER2- metastatic breast cancer. Brazilian Journal of Oncology 2025; 21.
DOI: 10.1055/s-0045-1807969